BACKGROUND: Immune activation is one of the main features of HIV/Hepatitis C virus (HCV) infections and has been linked to the disturbance of the gut-associated lymphoid tissue (GALT). In chronic HIV infection, loss of GALT integrity results in translocation of microbial products and chronic immune activation. We explored the relationship between bacterial translocation and specific colonic proteins, including liver expressed antimicrobial peptide (LEAP 2) which may play a role in modulating the bacterial translocation process. METHODS: A total of 40 subjects (10 HIV/HCV, 10 HIV, 10 HCV-infected patients and 10 controls) were enrolled and underwent serum and colonic tissue sampling. The levels of immune activation were evaluated by measuring plasma sCD27, and the levels of selected proinflammatory, Th2 and regulatory cytokines in both the plasma and supernatant of CD3-stimulated intraepithelial lymphocytes. We also evaluated LEAP-2 expression in the colon biopsies using Affymetrix Human Gene 1.0 ST (HuGene) and fluorescent immunohistochemistry. RESULTS: Increased levels of sCD27 were observed in HIV/HCV coinfected (p=0.03) and HIV monoinfected (p=0.04) patients compared with controls consistent with the presence of immune activation. The chip array identified LEAP-2 expression as a key marker associated with immune activation. LEAP-2 expression in HIV, HCV and HIV/HCV-infected patients was significantly lower compared with controls, and was significantly negatively correlated (p=0.03, r=-0.44) with sCD27. CONCLUSIONS: Our data suggests that HCV and HIV infections are associated with decreased expression of LEAP-2 in colonic tissue. This may represent a key mechanism for enhanced microbial translocation and immune activation in HIV/HCV-infected patients.
BACKGROUND: Immune activation is one of the main features of HIV/Hepatitis C virus (HCV) infections and has been linked to the disturbance of the gut-associated lymphoid tissue (GALT). In chronic HIV infection, loss of GALT integrity results in translocation of microbial products and chronic immune activation. We explored the relationship between bacterial translocation and specific colonic proteins, including liver expressed antimicrobial peptide (LEAP 2) which may play a role in modulating the bacterial translocation process. METHODS: A total of 40 subjects (10 HIV/HCV, 10 HIV, 10 HCV-infectedpatients and 10 controls) were enrolled and underwent serum and colonic tissue sampling. The levels of immune activation were evaluated by measuring plasma sCD27, and the levels of selected proinflammatory, Th2 and regulatory cytokines in both the plasma and supernatant of CD3-stimulated intraepithelial lymphocytes. We also evaluated LEAP-2 expression in the colon biopsies using Affymetrix Human Gene 1.0 ST (HuGene) and fluorescent immunohistochemistry. RESULTS: Increased levels of sCD27 were observed in HIV/HCV coinfected (p=0.03) and HIV monoinfected (p=0.04) patients compared with controls consistent with the presence of immune activation. The chip array identified LEAP-2 expression as a key marker associated with immune activation. LEAP-2 expression in HIV, HCV and HIV/HCV-infectedpatients was significantly lower compared with controls, and was significantly negatively correlated (p=0.03, r=-0.44) with sCD27. CONCLUSIONS: Our data suggests that HCV and HIV infections are associated with decreased expression of LEAP-2 in colonic tissue. This may represent a key mechanism for enhanced microbial translocation and immune activation in HIV/HCV-infectedpatients.
Authors: Ann Atlas; Tran Thi Thanh Ha; Anna Lindström; Anna Nilsson; Annette Alaeus; Francesca Chiodi; Angelo De Milito Journal: J Med Virol Date: 2004-03 Impact factor: 2.327
Authors: Jacob D Estes; Levelle D Harris; Nichole R Klatt; Brian Tabb; Stefania Pittaluga; Mirko Paiardini; G Robin Barclay; Jeremy Smedley; Rhonda Pung; Kenneth M Oliveira; Vanessa M Hirsch; Guido Silvestri; Daniel C Douek; Christopher J Miller; Ashley T Haase; Jeffrey Lifson; Jason M Brenchley Journal: PLoS Pathog Date: 2010-08-19 Impact factor: 6.823
Authors: N R Klatt; J D Estes; X Sun; A M Ortiz; J S Barber; L D Harris; B Cervasi; L K Yokomizo; L Pan; C L Vinton; B Tabb; L A Canary; Q Dang; V M Hirsch; G Alter; Y Belkaid; J D Lifson; G Silvestri; J D Milner; M Paiardini; E K Haddad; J M Brenchley Journal: Mucosal Immunol Date: 2012-05-30 Impact factor: 7.313
Authors: Asmaa M Zahran; Zeinab Albadry M Zahran; Omnia El-Badawy; Mona H Abdel-Rahim; Wageeh A M Ali; Amal Rayan; Muhammad Abbas El-Masry; Mohamed A A Abozaid; Helal F Hetta Journal: Immunol Res Date: 2019-06 Impact factor: 2.829
Authors: Helal F Hetta; Mohamed A Mekky; Nasr K Khalil; Wegdan A Mohamed; Mohamed A El-Feky; Shabaan H Ahmed; Enas A Daef; Mahmoud I Nassar; Ahmed Medhat; Kenneth E Sherman; Mohamed Tarek M Shata Journal: J Gastroenterol Hepatol Date: 2015-10 Impact factor: 4.029
Authors: Thomas A Premeaux; Carlee B Moser; Ashley McKhann; Martin Hoenigl; Stephen T Yeung; Alina P S Pang; Michael J Corley; Michael M Lederman; Alan L Landay; Sara Gianella; Lishomwa C Ndhlovu Journal: Open Forum Infect Dis Date: 2022-01-21 Impact factor: 4.423